

SELUTION SLR™ DEB DRUG ELUTION DONE BETTER

SUMMARY OF SELUTION4ISR TRIAL¹

A prospective, multi-center, randomized, single blind, controlled, non-inferiority clinical trial to demonstrate safety and efficacy of SELUTION SLR DEB vs. Standard of Care (SOC) in ISR.

418
PATIENTS

48
SITES



US
Canada
Brazil
Europe

SELUTION SLR DEB

(N=210)

VS

STANDARD OF CARE


(N=208)

80% DES | 20% POBA

STUDY RESULTS

**SELUTION SLR™ DEB IS AN ALTERNATIVE TO STANDARD
OF CARE IN ISR, MINIMIZING METAL.**

NON-INFERIOR: SELUTION SLR DEB VS SOC*



15.2%

TARGET LESION FAILURE
SELUTION SLR DEB

VS

13.5%

TARGET LESION FAILURE
STANDARD OF CARE


1. SELUTION4ISR Trial, Oral Presentation, TCT 2025

*Per protocol results (16.2% vs. 14.5%)

SELUTION SLR DEB


IS AN ALTERNATIVE TO SOC ACROSS ALL SUBGROUPS

SUBGROUP ANALYSIS OF THE PRIMARY ENDPOINT (ITT)



SELUTION SLR DEB

IS A SAFE ALTERNATIVE TO SOC



For Healthcare Professionals Only.

Important information: Prior to use, refer to the instructions for use supplied with this device or available at www.cordislabeling.com for indications, contraindications, suggested procedure, warnings, and precautions. As part of its continuous product development policy, Cordis reserves the right to change product specifications without prior notification. Please contact your Cordis representative for additional product availability information. SELUTION SLR Drug-Eluting Balloon is manufactured by MedAlliance, LLC and its affiliates. SELUTION SLR is a trademark of M.A. Med Alliance SA. MedAlliance, LLC and M.A. Med Alliance SA are Cordis companies. The SELUTION SLR PTCA DEB fulfills the requirements for CE marking certified at Notified Body 0344.

CORDIS and Cordis LOGO are Trademarks of Cordis and may be registered in the US and/or in other countries. All other marks are the property of their respective owners.

© 2026 Cordis. All Rights Reserved. 100673295-2



Scan the
QR Code to
learn more.

